Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWest China Hospital
About this trial
In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.
Eligibility criteria
Qualifiers
patients who underwent liver resection
patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC
Disqualifiers
patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy;
patients diagnosed with other specific types of sarcomas;
patients with concurrent other malignancies during the course of PHSC;
patients who were lost to follow-up or lacked essential clinical data.
Trial design
Treatments tested in this trial
- postoperative adjuvant therapy
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov